TabMenu

Poverty and InequalitySexual and Reproductive HealthFamily, Maternal & Child HealthMethodology

Pharmacokinetics and safety of tenofovir in HIV-infected women during labor and their infants during the first week of life

TitlePharmacokinetics and safety of tenofovir in HIV-infected women during labor and their infants during the first week of life
Publication TypeJournal Article
Year of Publication2014
AuthorsMirochnick, M, Taha, T, Kreitchmann, R, Nielsen-Saines, K, Kumwenda, N, Joao, E, Pinto, J, Santos, B, Parsons, T, Kearney, B, Emel, L, Herron, C, Richardson, P, Hudelson, SE, Eshleman, SH, George, K, Fowler, MG, Sato, P, Mofenson, L, Team, HP
JournalJ Acquir Immune Defic Syndr
Volume65
Pagination33-41
Date PublishedJan 01
ISBN Number1944-7884 (Electronic)1525-4135 (Linking)
Accession Number23979002
KeywordsAdenine/administration & dosage/adverse effects/*analogs &, Adolescent, Adult, Anti-HIV Agents/administration & dosage/adverse, derivatives/pharmacokinetics/therapeutic use, Drug Administration Schedule, effects/*pharmacokinetics/therapeutic use, Female, Fetal Blood/chemistry, HIV Infections/complications/*drug therapy, Humans, Infant, Newborn, Labor, Obstetric/*drug effects, Organophosphonates/administration & dosage/adverse, Pregnancy, Pregnancy Complications, Infectious/*drug therapy/metabolism, Tenofovir, Young Adult
Abstract

BACKGROUND: Data describing the pharmacokinetics and safety of tenofovir in neonates are lacking. METHODS: The HIV Prevention Trials Network 057 protocol was a phase 1, open-label study of the pharmacokinetics and safety of tenofovir disoproxil fumarate (TDF) in HIV-infected women during labor and their infants during the first week of life with 4 dosing cohorts: maternal 600 mg doses/no infant dosing; no maternal dosing/infant 4 mg/kg doses on days 0, 3, and 5; maternal 900 mg doses/infant 6 mg/kg doses on days 0, 3, and 5; maternal 600 mg doses/infant 6 mg/kg daily for 7 doses. Pharmacokinetic sampling was performed on cohort 1 and 3 mothers and all infants. Plasma, amniotic fluid, and breast milk tenofovir concentrations were determined by liquid chromatographic-tandem mass spectrometric assay. The pharmacokinetic target was for infant tenofovir concentration throughout the first week of life to exceed 50 ng/mL, the median trough tenofovir concentration in adults receiving standard chronic TDF dosing. RESULTS: One hundred twenty-two mother-infant pairs from Malawi and Brazil were studied. Tenofovir exposure in mothers receiving 600 and 900 mg exceeded that in nonpregnant adults receiving standard 300 mg doses. Tenofovir elimination in the infants was equivalent to that in older children and adults, and trough tenofovir plasma concentrations exceeded 50 ng/mL in 74%-97% of infants receiving daily dosing. CONCLUSIONS: A TDF dosing regimen of 600 mg during labor and daily infant doses of 6 mg/kg maintains infant tenofovir plasma concentration above 50 ng/mL throughout the first week of life and should be used in the studies of TDF efficacy for HIV prevention of mother-to-child transmission and early infant treatment.

PMCID

PMC3912736